Nutriband Inc. Board of Directors

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Mr. Gareth Sheridan

Mr. Gareth Sheridan

Founder, CEO & Director

Mr. Tyler Overk

Mr. Tyler Overk

Head of Active Intelligence

Dr. Jeffrey Patrick Pharm.D.

Dr. Jeffrey Patrick Pharm.D.

Chief Scientific Officer

Mr. Gerald Goodman

Mr. Gerald Goodman

CFO & Chief Accounting Officer

Dr. Alan Smith Ph.D.

Dr. Alan Smith Ph.D.

COO & President of 4P Therapeutics

Mr. Michael Myer

Mr. Michael Myer

President of Pocono Pharmaceutical

Mr. Serguei Melnik

Mr. Serguei Melnik

Founder, President, Company Secretary & Executive Chairman of the Board

Comments